Sensible Biotechnologies Analysis: $4M Raised
What is Sensible Biotechnologies?
Sensible Bio says it operates the first cell-based mRNA therapeutics platform. The company describes its technology as a cell-based mRNA design and manufacturing platform that produces pure, low-immunogenicity mRNA. Its site frames this as support for a new era of design-based biology.
Location
Oxford, United Kingdom
Employees
11-50
Founded
2021
Revenue
$1.3M
Business Model
Cell-based mRNA production platform; revenue from partnerships and funding rounds.
Product Features & Capabilities
- non-immunogenic mRNA, pure and highly functional mRNA, long mRNA for novel modalities, naturally modified mRNA for increased efficacy, cost-effective mRNA manufacturing, scalable mRNA production, cell-based platform for mRNA vaccines and therapeutics
How much Sensible Biotechnologies raised
Pre-Seed - $4.2 million
23 months agoLead Investor: Not specified in the sources.
Who are the founders of Sensible Biotechnologies
MG
Competitors Overview
Sensible Biotechnologies operates in the mRNA manufacturing market, focusing on a novel cell-based platform for producing high-quality mRNA therapeutics and vaccines. Its main competitors include:
-
Moderna: Known for its mRNA COVID-19 vaccine, Moderna has a robust pipeline of mRNA-based therapeutics. Its advantages include extensive experience in mRNA technology and significant financial backing, allowing for rapid development and scaling.
-
CureVac: This company specializes in mRNA technology for vaccines and therapeutics. CureVac's notable advantage is its proprietary mRNA backbone technology, which enhances the stability and efficacy of its products.
-
BioNTech: Initially recognized for its COVID-19 vaccine developed with Pfizer, BioNTech is expanding its mRNA platform for various therapeutic areas. Its strong partnerships and innovative approach to personalized medicine provide a competitive edge.
-
Thermo Fisher Scientific: A major player in the life sciences sector, Thermo Fisher offers comprehensive solutions for mRNA synthesis and manufacturing, including contract services. Its established market presence and broad service offerings make it a formidable competitor.
-
GenScript: This company provides a full-service solution for mRNA production, from gene synthesis to quality control. GenScript's integrated workflow and quick turnaround times are significant advantages in the competitive landscape.
-
Aldevron: Focused on plasmid DNA and mRNA production, Aldevron is known for its high-quality manufacturing capabilities. Its specialization in nucleic acid production positions it well in the mRNA market.
These competitors differ from Sensible Biotechnologies primarily in their established market presence, technological advancements, and financial resources, which allow them to scale operations and innovate rapidly.
Market Focus
Sensible Biotechnologies primarily focuses on the biotechnology industry, specifically in the area of mRNA manufacturing for therapeutics and vaccines.
Investors
- Sensible Biotechnologies raised $4.2 million in a pre-seed financing round.
- The investors involved in this round include:
- The Venture Reality Fund
- The University of California, Berkeley
- The University of California, San Francisco
- Various angel investors
See something that needs updating? Suggest edits to this profile.